Quality of life of treatment for relapsed/refractory multiple myeloma: a systematic review

被引：0
|
作者：
Nassim, Maria [1 ]
Nilsson, Jonas [1 ]
Zavisic, Stojan [2 ]
Malmenas, Mia [1 ]
Fotheringham, Iain [3 ]
Purushotham, Sneha [3 ]
机构：
[1] ICON Plc, Stockholm, Sweden
[2] Oncopeptides, Stockholm, Sweden
[3] ICON Plc, London, England
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2019年 / 19卷 / 10期
关键词：
Health related quality of life; Multiple myeloma; Quality of Life;
D O I：
10.1016/j.clml.2019.09.458
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
SP-132
引用
收藏
页码：E278 / E278
页数：1
相关论文
共 50 条
  • [41] Health Related Quality of Life (HRQoL) in Relapsed/Refractory Multiple Myeloma (RRMM): A Systematic Literature Review (SLR) and Meta-Analysis
    Banerjee, Rahul
    Hasegawa, Ken
    Itani, Taha
    Giordana, Monique
    Granados, Enrique
    Rosado, Margrit B.
    Chan, Rebecca J.
    Kostic, Ana
    Kanters, Steve
    Zoratti, Michael J.
    Leleu, Xavier
    BLOOD, 2024, 144 : 4721 - 4722
  • [42] Efficacy of ixazomib for the treatment of relapsed/refractory multiple myeloma A protocol of systematic review and meta-analysis
    Li, Zhi
    Guo, Shu-Li
    Wang, Wan-Li
    MEDICINE, 2020, 99 (20)
  • [43] Systematic Literature Review and Network Meta-Analysis of Treatment Outcomes in Relapsed and/or Refractory Multiple Myeloma
    van Beurden-Tan, Chrissy H. Y.
    Franken, Margreet G.
    Blommestein, Hedwig M.
    Uyl-de Groot, Carin A.
    Sonneveld, Pieter
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (12) : 1312 - +
  • [44] Real-World Outcomes for the Treatment of Relapsed/Refractory Multiple Myeloma With Daratumumab: A Systematic Literature Review
    Gros Otero, B.
    Gungor, G.
    Gruppe, T. L.
    Wan, M.
    Jenkins, C.
    Helme, K.
    VALUE IN HEALTH, 2022, 25 (12) : S494 - S494
  • [45] Comparative Effectiveness of Lenalidomide Plus Dexamethasone for the Treatment of Refractory/Relapsed Multiple Myeloma: A Systematic Review and Mixed Treatment Comparison
    Stradwick, Sallie
    Freemantle, Nick
    Snowden, John
    Rodrigues, Felipe
    Brereton, Nic
    BLOOD, 2012, 120 (21)
  • [46] Correction to: Daratumumab: A Review in Relapsed and/or Refractory Multiple Myeloma
    Hannah A. Blair
    Drugs, 2018, 78 : 397 - 397
  • [47] Patient Perspectives on Treatment Experience and Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma
    Nathwani, Nitya
    Bell, Jill A.
    Cherepanov, Dasha
    Sowell, France Ginchereau
    Shah, Rachel
    McCarrier, Kelly
    Hari, Parameswaran
    BLOOD, 2020, 136
  • [48] Profile and management of toxicity of selinexor and belantamab mafodotin for the treatment of relapsed/refractory multiple myeloma: A systematic review.
    Neupane, Karun
    Ehsan, Hamid
    Wahab, Ahsan
    Masood, Adeel
    Ahmed, Tehniat Faraz
    Bahram, Saman
    Hannan, Abdul
    Haider, Mobeen Zaka
    Shahzad, Moazzam
    Mushtaq, Muhammad Umair
    Anwer, Faiz
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [49] Efficacy and safety of daratumumab for the treatment of refractory/relapsed multiple myeloma. A systematic review of meta-analyses
    Moustafa, Diala Alhaj
    Shafei, Laila
    Sulaiman, Ruba
    Yassin, Mohamed A.
    Abushanab, Dina
    Algarabli, Yousef
    Al-Badriyeh, Daoud
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2025, 31 (02) : 266 - 275
  • [50] Health-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myeloma
    Delforge, Michel
    Shah, Nina
    Miguel, Jesus San F.
    Braverman, Julia
    Dhanda, Devender S.
    Shi, Ling
    Guo, Shien
    Yu, Peiwen
    Liao, Weiqin
    Campbell, Timothy B.
    Munshi, Nikhil C.
    BLOOD ADVANCES, 2022, 6 (04) : 1309 - 1318
12345